Basingstoke, U.K. and Philadelphia, PA – August 26, 2008 – Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has announced that VYVANSE is now available in U.S.

The maker of the ADHD drug Vyvanse has been given approval by the US Drug Enforcement Administration to make more of the medication as a shortage of the critical drugs continues. HealthDay News — The ...

Medically reviewed by Lindsay Cook, PharmD Key Takeaways Concerta and Vyvanse are both long-acting stimulant medications ...

In a significant move to mitigate the ongoing shortage of ADHD medications in the U.S., the Drug Enforcement Administration (DEA) has authorized a substantial increase in the production limits for ...

To address the nationwide shortage of medications for attention-deficit/hyperactivity disorder, the Drug Enforcement Administration is allowing an increase in the ...

LONDON (Reuters) - Shire has struck a deal with GlaxoSmithKline, the world's second largest drugs group, to co-promote its hyperactivity medicine Vyvanse in the United States, sending its shares ...

One pharmaceutical manufacturer is recalling lots of generic Vyvanse over failed dissolution tests. Medication may not be working as it should.

PHILADELPHIA – May 22, 2009 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced results of a study showing that coadministration of the ADHD medication ...

WASHINGTON — The Drug Enforcement Administration has increased the production limit for the ADHD drug Vyvanse and its generic versions to combat the medicine's ongoing shortage, according to a notice ...

Supply from drugmakers for the stimulant medications most commonly prescribed for ADHD are still falling short of demand, the Food and Drug Administration says, and many Americans who rely on these ...